ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101 - Takeaways - MDSpire

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

Share

  • 1

    The A-DREAM/Alliance A032101 study was presented by Dr. Atish Choudhury from Dana-Farber Cancer Institute.

  • 2

    41% of favorable responders achieved treatment-free status after testosterone suppression and androgen receptor pathway inhibitor.

  • 3

    Participants maintained testosterone recovery at 18 months following treatment interruption.

  • 4

    The study focuses on the effects of testosterone suppression in cancer treatment.

  • 5

    Results indicate a significant proportion of patients can remain treatment-free post-therapy.

Original Source(s)

ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

  • July 1, 2026

Related Content

Evaluating the accuracy and communication quality of large language models in Ewing sarcoma: a comparative analysis of ChatGPT, Claude, Gemini, DeepSeek, and Grok

Established and emerging prognostic factors in mycosis fungoides and Sézary syndrome

Development and validation of multidimensional nomograms for predicting prostate cancer risk: a retrospective study